ストックスクリーナーアプリを入手
6.98
1.27%
-0.09
アフターアワーズ：
6.98
前日終値:
$7.07
開ける：
$7
24時間の取引高:
77,531
Relative Volume:
1.27
時価総額：
$192.74M
収益：
-
当期純損益:
$-35.46M
株価収益率:
-16.55
EPS:
-0.4218
ネットキャッシュフロー:
$-34.00M
1週間 パフォーマンス:
-10.05%
1か月 パフォーマンス:
-0.85%
6か月 パフォーマンス:
-63.53%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$6.822
$7.20
1週間の範囲:
$6.822
$7.995
52週間の値動き範囲:
$5.92
$22.00
Contineum Therapeutics Inc Stock (CTNM) Company Profile
名前
Contineum Therapeutics Inc
セクター
電話
(858) 333-5280
住所
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
CTNM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
6.98 | 192.74M | 0 | -35.46M | -34.00M | -0.4218 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-22 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-30 | 開始されました | Morgan Stanley | Overweight |
| 2024-04-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-04-30 | 開始されました | Stifel | Buy |
Contineum Therapeutics Inc (CTNM) 最新ニュース
Charles Schwab Investment Management Inc. Has $811,000 Stock Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Bank of New York Mellon Corp Has $275,000 Stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Long Term Trading Analysis for (CTNM) - news.stocktradersdaily.com
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors - BioSpace
Pharma Veteran Diego Miralles Joins Contineum Board as Company Preps Multiple Clinical Trials - StockTitan
Analysts Set Contineum Therapeutics, Inc. (NASDAQ:CTNM) Target Price at $24.80 - Defense World
(CTNM) Investment Report - news.stocktradersdaily.com
Jones Trading Begins Coverage on Contineum Therapeutics (NASDAQ:CTNM) - Defense World
Jones Trading Initiates Coverage of Contineum Therapeutics (CTNM) with Buy Recommendation - Nasdaq
JonesTrading Initiates Contineum Therapeutics at Buy With $23 Price Target -March 13, 2025 at 08:48 am EDT - Marketscreener.com
Institutional investors in Contineum Therapeutics, Inc. (NASDAQ:CTNM) have had a wonderful week after share price increased 24% - Yahoo Finance
Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum - Eagle-Tribune
Rhumbline Advisers Acquires 2,191 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics’ (CTNM) “Overweight” Rating Reiterated at Morgan Stanley - Defense World
Robert W. Baird Cuts Contineum Therapeutics (NASDAQ:CTNM) Price Target to $16.00 - Defense World
Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones - Marketscreener.com
Contineum reports Q4 EPS (56c), consensus (44c) - TipRanks
Contineum Therapeutics, Inc. SEC 10-K Report - TradingView
Objective long/short (CTNM) Report - Stock Traders Daily
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791 - Marketscreener.com
Can Contineum's New Non-Opioid Drug Revolutionize Chronic Pain Treatment? - StockTitan
Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference - Business Wire
Clinical-Stage Biotech Contineum Sets Stage for Key Investor Presentation at Leerink Conference - Stock Titan
Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights - Quantisnow
Contineum Therapeutics (CTNM) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Can Contineum's Upcoming Catalysts Turn The Tide In The Coming Months? - RTTNews
How To Trade (CTNM) - Stock Traders Daily
Chief Executive Officer Monia Brett P sold $1,229,463 worth of shares (38,843 units at $31.65), decreasing direct ownership by 18% to 180,683 units (SEC Form 4) - Quantisnow
Multiple Sclerosis FDA Approvals, Clinical Trials, Emerging Drugs, Pipeline Insights and Companies | DelveInsight - Barchart
Contineum Therapeutics (CTNM) Projected to Post Quarterly Earnings on Wednesday - Defense World
(CTNM) Investment Analysis and Advice - Stock Traders Daily
Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
Barclays PLC Increases Stock Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Contineum Therapeutics, Inc.'s (NASDAQ:CTNM) 12% loss last week hit both individual investors who own 37% as well as institutions - Simply Wall St
New Oriental Education, Walgreens And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Contineum concludes enrolment in Phase II multiple sclerosis therapy trial - MSN
Enrollment complete in Phase 2 trial of remyelination therapy for RRMS - Multiple Sclerosis News Today
Contineum Therapeutics (NASDAQ:CTNM) Earns “Outperform” Rating from Royal Bank of Canada - Defense World
Contineum Therapeutics' (CTNM) "Outperform" Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - BioSpace
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference - Quantisnow
Contineum Therapeutics, Inc. Completes Enrollment in Phase 2 PIPE-307 Vista Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis - Marketscreener.com
Barclays PLC Raises Stock Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Geode Capital Management LLC Sells 27,745 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Completes Enrollment Early for Groundbreaking Multiple Sclerosis Treatment Trial - Stock Titan
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors - The Manila Times
State Street Corp Raises Stock Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Short Interest Update - MarketBeat
When the Price of (CTNM) Talks, People Listen - Stock Traders Daily
Contineum Therapeutics Inc (CTNM) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):